Background: Robot-assisted surgery (RAS) is expanding rapidly across surgical specialities, yet adoption across the globe remains variable. There is growing recognition to expand RAS across all healthcare settings, to ensure equity of access and improve clinical outcomes for all patients. Facilitating the expansion of RAS requires the development of high-quality, durable and sustainable RAS programmes. The aim of the RoboDev study was to develop a universal, globally applicable guideline to aid development and expansion of RAS programmes. Methods: The RoboDev study was conducted as an international, multistakeholder Delphi process consisting of four phases: (1) scoping review and item generation, (2) questionnaire design and pre-testing, (3) accelerated two-round Delphi survey, and (4) consensus meetings. Participants were stratified by World Bank income classification. Recommendations achieving ≥80% agreement were retained. A subset of participants subsequently evaluated the final recommendations using the APEASE criteria (Acceptability, Practicability, Effectiveness, Affordability, Spill-over effects, and Equity). Results: A total of 1,000 participants completed Round 1 and 812 completed Round 2 of the Delphi, representing HIC (59.5%), UMIC (16.6%), LMIC (18.7%), and LIC (1.6%) stakeholders. From 245 initial statements across eight domains, 194 recommendations achieved global consensus. Tailored adaptations were added for each income group, resulting in 197 recommendations for HICs, 207 for UMICs, 206 for LMICs, and 216 for LICs. Training, infrastructure readiness, and multidisciplinary engagement showed the greatest variation across settings. APEASE evaluation confirmed overall acceptability, practicality, and equity, with LIC participants reporting the highest spill-over and equity benefits. Conclusion: The RoboDev study has developed the first global, evidence-based, and context-sensitive guidelines for building and expanding robot-assisted surgical programmes. By combining universal principles with context-specific adaptations, these recommendations provide a roadmap for equitable and sustainable expansion of robotic surgery worldwide. Adoption of these guidelines has the potential to improve patient outcomes, strengthen surgical systems and ensure that the benefits of robotic innovation are shared equitably across all global contexts.
4109 Background: Biliary tract cancers (BTC) present significant challenges in management due to their aggressive nature and often late-stage presentation. We present demographic trends, molecular characteristics, treatment patterns, and survival outcomes. Methods: This retrospective study included patients diagnosed with BTC between March 2018 and September 2024. Survival analysis was done using the Kaplan-Meier analysis. Results: Total of 743 patients were diagnosed with BTC, median age of the cohort was 61 years (IQR 52-69); with F: M ratio being 1.15:1. Distribution according to the stage at presentation was: stage I (n=15, 2%), stage II (n=49,6.6%), Stage III (n=160, 21.5%) and stage IV (n=509, 68.5%). History of gallstones was reported in 183 patients (24.6%). Out of the total cohort, 436 patients (58.7%) had gallbladder cancers (GBCs) while 307 patients (41.3%) had cholangiocarcinoma (CCA), where n=202 (65.8%) were intrahepatic, n=22 (7.2%) were perihilar and n=33 (10.7%) were distal bile duct. Predominant histologic patterns among GBCs were: adenocarcinomas n=331 (75.9%), small cell carcinomas n=13(3%) adenosquamous n=11(2.5%), and others n=81(18.5%). Molecular testing was done in 132 patients (17.8%), out of which 11/132 (8.3%) had HER2 alteration, wherein overexpression was seen in n=3,while amplification was seen in n=8; TP53 mutation was seen in 21/132 (16%), while others alterations were MSI-high (n=2), TMB-high (≥10 mut/Mb) (n=3), PDL1 positive (n=24), FGFR(n=3), IDH (n=2), BRCA2 (n=2). Treatment and survival outcomes were available for 492 patients, surgery was done in 177 patients (35.9%), systemic therapy (adjuvant/palliative) was done in 431 (87.6%) patients while targeted or immunotherapy was used in 99 patients (20.1%). Median Overall survival (mOS) of the cohort was 16.1 months (13.6-18.6) with a median follow-up duration of 28.2 months (23.2 – 33.2). mOS for GBC was 10.8(8.2-13.3) months and CCA was11.6(9.3-14.0) months. mOS for Metastatic BTC was 9.6 months while for Non-metastatic it was 20.4 months(p<0.001). The median mOS for patients with HER2 mutations, TP53 mutations, and PD-L1 positivity were 23.8 months, 16.6 months, and 10.0 months, respectively (p = 0.165). Conclusions: In high-prevalence countries like India, biliary tract cancer (BTC) management is challenged by advanced stage presentation, limited molecular testing and resource constraints. Efforts to enhance molecular testing and treatment access are critical for practicing precision oncology and improving treatment outcomes.
e15074 Background: We hereby present the meta analysis from molecular profiling of NSCLC patients treated at our centre over the past 2 years. NSCLC accounts for 10.4% (n = 1768) of newly detected solid cancers at our centre. 20–30% patients exhibit lack of durable response to respective 1 st line therapeutic regimes. This study aims to understand genomic factors contributing towards therapeutic resistance and necessitating combinatorial regimes. Methods: We analyzed CGP results of 242 treatment naïve lung cancer patients across 2 years & studied co-occurring mutations pertaining to downstream pathways including tyrosine kinase pathway, mTOR/AKT/PI3kinase pathway, CDK4/6 pathway, RAS/RAF/MEK/ERK pathway and others, to further understand the impact of such genomic alterations on 1 st line therapy. In this study we included only newly diagnosed cases of NSCLC who were previously untreated (therapy naïve). Results: We observed that 47.5% (115/242) were EGFR-mut while 52.5% (127/242) were EGFR-wt. From the EGFR-mut cohort 48% (55/115) revealed presence of singular alterations that were sensitive to 1 st line EGFR TKIs while 52% (60/115) had accompanying secondary genomic alterations. From the EGFR-wt cohort 22% (27/127) did not reveal any other somatic alteration while 78% (100/127) contained other therapeutically relevant mutations. Secondary genomic alterations observed in EGFR-mut cases were further subdivided into two categories: a. Mutations involving a singular oncogenic driver pathway [80% (48/60)] and, b. Mutations involving multiple oncogenic driver pathways [20% (12/60)]. Secondary genomic alterations observed in EGFR wild type cases were subdivided into three categories: a. druggable - harbouring singular non-EGFR gene alterations (eg. ALK etc) 21% (21/100), b. co-occurring mutations involving multiple non-EGFR oncogenic driver pathways 16% (16/100) (eg. ALK fusions co-occurring with KRAS mutation) and, c. Genomic alterations devoid of approved 1 st line target therapy i.e those who were treated with chemotherapeutic regimes 64% (64/100) (eg. KRAS G12D). Across the board, patients with somatic mutations in TP53 at baseline performed relatively poorer in both target therapy and chemotherapy arms. Conclusions: 28% (68/242) patients harboured resistance imparting genomic alterations at baseline. This analysis reveals the staggering prevalence of resistance causing genomic alterations in NSCLC patients at baseline & co-relates with PFS of 1 years or less on 1 st line therapy. We hypothesize that combinatorial therapeutic approaches like those of combining EGFR TKIs with chemotherapy, CDK4/6i, mTORi, MEKi and other agents will make significant impact in PFS and OS. Also comprehensive somatic NGS profiling must necessarily be included in pre-therapeutic workup of all NSCLC patients so as to ensure better response and survival.
8070 Background: Next Generation Sequencing (NGS)-guided targeted therapy is a standard practice in lung cancer, as recommended by professional guidelines. Various gene panels, exome, and genome sequencing strategies are employed to detect therapeutic targets. Selecting the right test is critical for achieving favorable patient outcomes. This study compares the efficacy and clinical utility of gene panels and exome sequencing in stratifying patients for different therapeutic options. Methods: We retrospectively analyzed genomic profiles of 1,224 advanced lung cancer patients (Stage III and Stage IV) sequenced using small gene panel (SP; 72 genes, NCCN biomarker driven TarGT First) and broad gene panel (BP; 1,212 genes, NCCN and pathways driven TarGT IndieGene. Tumor FFPE samples were screened for SNVs/InDels, CNVs, gene fusions, and immunotherapy biomarkers, including TMB, MSI, and PD-L1 expression. Results: Among the 1,224 patients, 791 were screened with small panels, 552 with broad panels, and 42 with exome sequencing. Sequencing with BP identified at least one driver/pathogenic mutation in 89.7% patients, which was higher than that detected in SP (73.6%). BP detected a higher proportion of patients with therapeutically targetable variants than SP (80.6% vs. 73.3%). Both SP and BP detected equivalent proportion of patients as eligible for level 1 (FDA-approved) therapy (SP 38.7% vs. BP 37.5%) and level 2 therapy (3.2% vs. 4%) and while a significantly higher number of patients eligible for level 3 (clinical trials) therapies were detected in BP (SP 31.5% vs. BP 39.1%). In a subset of 172 patients screened with both SP and BP. BP identified driver/pathogenic mutations in all patients (100% diagnostic yield) while SP identified mutations in 62.8% of the patients. BP also detected targetable variants in 84.9% of cases, compared to 62.8% detected in SP. Patients eligible for FDA-approved therapy (48.3% vs. 41.9%), off-label therapy (5.2% vs. 3.5%), and clinical trial therapies (38.4% vs. 17.4%) were more frequently detected with BP than in SP. Conclusions: BP outperform SP in detecting clinically significant drivers and therapeutic biomarkers, demonstrating their utility in precision oncology. This study highlights the advantages of comprehensive genomic profiling (CGP) over small panels for guiding prognosis and therapy decisions in advanced lung cancer during disease progression. Patients with targetable variants (No. of patients; %) Level 1 therapy(No. of patients; %) Level 2 therapy (No. of patients; %) Level 3 therapy (No. of patients; %) No therapy(No. of patients; %) Small panel sequencing (SP)(n=791 patients) 580; 73.3% 306; 38.7% 25; 3.2% 249; 31.5% 211; 26.7% Broad panel sequencing (BP)(n=552 patients) 445; 80.6% 207; 37.5% 22; 4% 216; 39.1% 107; 19.4%